跳至主要内容
临床试验/EUCTR2008-005659-83-NL
EUCTR2008-005659-83-NL进行中(未招募)不适用

Second IVIg Dose in GBS patients with poor prognosis (SID-GBS trial) - SID-GBS trial

Erasmus MC0 个研究点开始时间: 2009年9月9日最近更新:
相关药物

试验速览

阶段
不适用
状态
进行中(未招募)
发起方
Erasmus MC

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • diagnosed with GBS according to the international accepted criteria, given informed consent, patient in grade 3, 4 or 5 of the GBS disability scale or is there otherwise an indication for IVIg therapy according to the treating neurologist, less than two weeks since onset of weakness, able to attend follow-up of 6 months.
  • Are the trial subjects under 18? yes
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 60
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 10

排除标准

  • age below 6 years, severe allergic reaction to properly matched blood products, known to have severe concurrent disease, having selective IgA deficiency, clinical evidence of polyneuropathy caused by other cause than GBS, received immune suppressive therapy during last month, pregnant or breast feeding.

研究者

发起方
Erasmus MC

相似试验